Company Overview of Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc., a biotechnology company, focuses on developing immunotherapies for the treatment of cancer. Its product pipeline comprises ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers; ET601, an extracellular tumor antigen; intra and extracellular tumor antigens, immuno-modulatory checkpoints; and intracellular oncogenes. The company’s human antibody products reach inside a cancer cell to recognize cancer-associated proteins and then mobilize the immune system to attack the cancer cell. It also provides contract research services, such as antibody chimerization and humanization, antibody affinity maturation, CHO cell line developmen...
5858 Horton Street
Emeryville, CA 94608
Founded in 2006
Key Executives for Eureka Therapeutics, Inc.
Co-Founder and Chief Executive Officer
Head of Business Operations
Compensation as of Fiscal Year 2015.
Eureka Therapeutics, Inc. Key Developments
Eureka Therapeutics Inc. and Boehringer Ingelheim Announce Collaboration to Identify Next Generation Antibodies for Cancer Treatment
May 22 15
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to Identify Next Generation Antibodies for Cancer Treatment. This collaboration underlines long-term commitment to oncology and interest in exploring new target spaces with antibodies that recognize intracellular proteins. It will open up entirely new opportunities for the development of tumor cell- as well as immune cell-targeted therapies. The company are looking forward to working closely with Eureka?s scientists to develop novel, effective therapies targeting cancers that have proved particularly difficult to treat in the past, said Dr. Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim.
Memorial Sloan Kettering and Eureka Therapeutics Signs Licensing Agreement with Novartis
Jan 29 14
Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. announced that it have entered into a licensing agreement with Novartis AG for the development and commercialization of ESK1, a preclinical stage monoclonal antibody for the treatment of leukemia and other cancers. Memorial Sloan Kettering is a cancer hospital that provides cancer care services, while Eureka Therapeutics is a biotechnology company that focuses on the discovery of human antibody drugs for the treatment of cancer. Both the companies are based in the United States. The ESK1 developed by Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center. Under the terms of the agreement, Eureka Therapeutics and Memorial Sloan-Kettering will receive an up front payment and potential future payments upon achievement of development, regulatory and sales milestones, and annual net sales royalty payments. Novartis will fund and execute all additional development and commercialization activities.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 20, 2014
Most Searched Private Companies
Sponsored Financial Commentaries